


## Central Lancashire Online Knowledge (CLoK)

Title	Geographic disparity of pathophysiological coronary artery disease characteristics: Insights from ASET trials
Type	Article
URL	<a href="https://clock.uclan.ac.uk/50596/">https://clock.uclan.ac.uk/50596/</a>
DOI	##doi##
Date	2024
Citation	Kotoku, Nozomi, Ninomiya, Kai, Masuda, Shinichiro, Tsai, Tsung Ying, Revaiah, Pruthvi C, Garg, Scot, Kageyama, Shigetaka, Tu, Shengxian, Kozuma, Ken et al (2024) Geographic disparity of pathophysiological coronary artery disease characteristics: Insights from ASET trials. <i>International Journal of Cardiology</i> , 400 . ISSN 0167-5273
Creators	Kotoku, Nozomi, Ninomiya, Kai, Masuda, Shinichiro, Tsai, Tsung Ying, Revaiah, Pruthvi C, Garg, Scot, Kageyama, Shigetaka, Tu, Shengxian, Kozuma, Ken, Kawashima, Hideyuki, Ishibashi, Yuki, Nakazawa, Gaku, Takahashi, Kuniaki, Okamura, Takayuki, Miyazaki, Yosuke, Tateishi, Hiroki, Nakamura, Masato, Kogame, Norihiro, Asano, Taku, Nakatani, Shimpei, Morino, Yoshihiro, Ishida, Masaru, Katagiri, Yuki, De Martino, Fernando, Tinoco, João, Guimarães, Patricia O, Tanabe, Kengo, Ozaki, Yukio, Muramatsu, Takashi, Lemos, Pedro A, Onuma, Yoshinobu and Serruys, Patrick W

It is advisable to refer to the publisher's version if you intend to cite from the work. ##doi##

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>



## Geographic disparity of pathophysiological coronary artery disease characteristics: Insights from ASET trials

Nozomi Kotoku<sup>a,1</sup>, Kai Ninomiya<sup>a,1</sup>, Shinichiro Masuda<sup>a</sup>, Tsung Ying Tsai<sup>a</sup>, Pruthvi C. Revaiah<sup>a</sup>, Scot Garg<sup>b,c</sup>, Shigetaka Kageyama<sup>a</sup>, Shengxian Tu<sup>d</sup>, Ken Kozuma<sup>e</sup>, Hideyuki Kawashima<sup>e</sup>, Yuki Ishibashi<sup>f</sup>, Gaku Nakazawa<sup>g</sup>, Kuniaki Takahashi<sup>g</sup>, Takayuki Okamura<sup>h</sup>, Yosuke Miyazaki<sup>h</sup>, Hiroki Tateishi<sup>h,i</sup>, Masato Nakamura<sup>j</sup>, Norihiro Kogame<sup>j,k</sup>, Taku Asano<sup>l</sup>, Shimpei Nakatani<sup>m</sup>, Yoshihiro Morino<sup>n</sup>, Masaru Ishida<sup>n</sup>, Yuki Katagiri<sup>o</sup>, Fernando De Martino<sup>p</sup>, João Tinoco<sup>q</sup>, Patricia O. Guimarães<sup>r,s</sup>, Kengo Tanabe<sup>t</sup>, Yukio Ozaki<sup>u</sup>, Takashi Muramatsu<sup>v</sup>, Pedro A. Lemos<sup>r,s</sup>, Yoshinobu Onuma<sup>a</sup>, Patrick W. Serruys<sup>a,\*</sup>, On behalf of the ASET Japan and ASET Brazil Investigators

<sup>a</sup> Department of Cardiology, University of Galway, Galway, Ireland

<sup>b</sup> Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom

<sup>c</sup> School of Medicine, University of Central Lancashire, Preston, United Kingdom

<sup>d</sup> School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China

<sup>e</sup> Department of Cardiology, Teikyo University Hospital, Tokyo, Japan

<sup>f</sup> Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan

<sup>g</sup> Department of Cardiology, Kindai University Faculty of Medicine, Osaka, Japan

<sup>h</sup> Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

<sup>i</sup> Department of Cardiology, Heart Clinic Minami Yamaguchi, Yamaguchi, Japan

<sup>j</sup> Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan

<sup>k</sup> Department of Cardiology, Tokyo Rosai Hospital, Tokyo, Japan

<sup>l</sup> Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan

<sup>m</sup> Department of Cardiology, JCHO Hoshigaoka Medical Center, Osaka, Japan

<sup>n</sup> Department of Cardiology, Iwate Medical University Hospital, Iwate, Japan

<sup>o</sup> Department of Cardiology, Sapporo Higashi Tokushukai Hospital, Hokkaido, Japan

<sup>p</sup> Department of Internal Medicine, Discipline of Cardiology, University of Triangulo Mineiro, Uberaba, Brazil

<sup>q</sup> Instituto Cardiovascular de Linhares UNICOR, Linhares, Espírito Santo, Brazil

<sup>r</sup> Heart Institute – InCor, University of São Paulo, São Paulo, Brazil

<sup>s</sup> Hospital Israelita Albert Einstein, Sao Paulo, Brazil

<sup>t</sup> Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan

<sup>u</sup> Department of Cardiology, Fujita Health University Okazaki Medical Center, Aichi, Japan

<sup>v</sup> Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan

### ARTICLE INFO

#### Keywords:

Coronary artery disease  
Diffuse disease  
Geographic disparity  
Percutaneous coronary intervention  
Pullback pressure gradient  
Quantitative flow ratio

### ABSTRACT

**Background:** The geographical disparity in the pathophysiological pattern of coronary artery disease (CAD) among patients undergoing percutaneous coronary intervention (PCI) is unknown.

**Objectives:** To elucidate the geographical variance in the pathophysiological characteristics of CAD.

**Methods:** Physiological indices derived from angiography-based fractional flow reserve pullbacks from patients with chronic coronary syndrome enrolled in the ASET Japan ( $n = 206$ ) and ASET Brazil ( $n = 201$ ) studies, which shared the same eligibility criteria, were analysed.

**Abbreviations:** CAD, coronary artery disease;  $d\mu\text{QFR}/ds$ ,  $\mu\text{QFR}$  gradient per mm; FFR, fractional flow reserve; PCI, percutaneous coronary intervention; PPG, pullback pressure gradient;  $\mu\text{QFR}$ , Murray law-based quantitative flow ratio.

\* Corresponding author at: University of Galway, University Road, Galway H91 TK33, Ireland.

E-mail address: [patrick.w.j.c.serruys@gmail.com](mailto:patrick.w.j.c.serruys@gmail.com) (P.W. Serruys).

<sup>1</sup> N. Kotoku and K. Ninomiya contributed equally to this manuscript

<https://doi.org/10.1016/j.ijcard.2024.131805>

Received 3 November 2023; Received in revised form 31 December 2023; Accepted 18 January 2024

Available online 23 January 2024

0167-5273/© 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

The pathophysiological patterns of CAD were characterised using Murray law-based quantitative flow ratio ( $\mu$ QFR)-derived indices acquired from pre-PCI angiograms. The diffuseness of CAD was defined by the  $\mu$ QFR pullback pressure gradient index.

**Results:** Significant functional stenoses pre-PCI ( $\mu$ QFR  $\leq 0.80$ ) were more frequent in ASET Japan compared to ASET Brazil (89.9% vs. 67.5%,  $p < 0.001$ ), as were rates of a post-PCI  $\mu$ QFR  $< 0.91$  (22.1% vs. 12.9%,  $p = 0.013$ ). In the multivariable analysis, pre-procedural  $\mu$ QFR and diffuse disease were independent factors for predicting a post-PCI  $\mu$ QFR  $< 0.91$ , which contributed to the different rates of post-PCI  $\mu$ QFR  $\geq 0.91$  between the studies. Among vessels with a post-PCI  $\mu$ QFR  $< 0.91$ , a consistent diffuse pattern of CAD pre- and post-PCI occurred in 78.3% and 76.7% of patients in ASET Japan and Brazil, respectively; only 6.3% (Japan) and 10.0% (Brazil) of vessels had a major residual gradient. Independent risk factors for diffuse disease were diabetes mellitus in ASET Japan, and age and male gender in Brazil.

**Conclusions:** There was geographic disparity in pre-procedural angiography-based pathophysiological characteristics. The combined pre-procedural physiological assessment of vessel  $\mu$ QFR and diffuseness of CAD may potentially identify patients who will benefit most from PCI.

## 1. Introduction

Cardiovascular disease remains a major cause of mortality worldwide, however there is a geographic disparity in its prevalence, treatment and management strategies for modifiable, non-genetic risk factors [1]. Among the five primary risk factors for coronary artery disease (CAD)—hypertension, hyperlipidaemia, obesity, smoking, and diabetes mellitus—diabetes mellitus poses a greater burden in Asia, while the other four are more prevalent in Europe and Central Asia compared to other regions of the world [2].

In Japan, patients undergoing percutaneous coronary intervention (PCI) are typically older and have higher rates of diabetes, hypertension, and complex lesions compared to those in Europe [3,4]. Moreover, the J-Cypher and Bern-Rotterdam registries revealed lower mortality and stent thrombosis rates in the Japanese cohort at five years [3]. In contrast, Kohsaka et al. reported that, compared to patients undergoing revascularisation in Japan, those in the United States presented with higher obesity rates and frequency of previous atherosclerosis-related events such as myocardial infarction, peripheral vascular disease, renal insufficiency, and hypertension [5]. Understanding the geographic (and ethnic) disparities in cardiovascular disease and risk factors could support the development of effective prevention efforts since each population epitomises diverse political histories and a variety of social, economic, and cultural backgrounds that can influence cardiovascular health in different ways [6].

The advent of angiography-based fractional flow reserve (FFR) has advanced the functional assessment of coronary stenoses by eliminating the need for wire and hyperemic agents, thus reducing procedural time and patient discomfort compared to conventional intracoronary pressure measurements [7]. Angiography-based FFR allows the generation of a virtual pullback curve and characterisation of pathophysiological patterns of CAD as well as discrimination of the physiological contribution of every single lesion [8]. Recent studies highlight the role of preprocedural pathophysiological CAD patterns, characterised by the magnitude and distribution of the pressure drop along the target vessel using wire-based or angiography-based FFR pullback pressure gradients, in predicting the physiological response to PCI and subsequent clinical outcomes [9–15].

While earlier investigations have identified disparities in atherosclerosis risk factors and baseline clinical and lesion characteristics across diverse geographical populations, the potential variation in pathophysiological patterns of epicardial CAD among those undergoing contemporary PCI remains unexplored. We hypothesised that geographical variance in pathophysiological patterns of CAD, as well as in baseline clinical characteristics, might exist between patients undergoing PCI in the Far East and South America. To test this hypothesis, we pooled and compared physiological indices derived from angiography-based FFR virtual pullbacks of patients enrolled in the ASET Japan and ASET Brazil studies, which both shared the same eligibility criteria.

## 2. Methods

### 2.1. Study population

This study included 206 and 201 consecutive patients with chronic coronary syndrome (CCS) enrolled in the ASET (Acetyl Salicylic Elimination Trial) Japan (NCT05117866) and the ASET Brazil study (NCT03469856), respectively.

The study design and results were previously reported [16–19]. Briefly, both studies are multi-centre, single-arm, open-label, proof-of-concept trials—with a stopping rule based on the occurrence of definite stent thrombosis—that demonstrated the feasibility and safety of “aspirin-free” therapy with prasugrel monotherapy following PCI in Japanese and Brazilian population with CCS, respectively.

These two studies shared the same eligibility criteria with different dosages of Prasugrel according to local regulatory approval. The inclusion and exclusion criteria have been previously reported [16,19]. Briefly, in both studies, patients requiring PCI for CCS who had an anatomical SYNTAX score  $< 23$  were screened and considered for enrolment. Only patients with optimal stent implantation based on the local standard of care (i.e., angiography, quantitative coronary angiography [QCA], intracoronary imaging assessment) were enrolled.

The studies were approved by the certified review boards at the Fujita Health University (CRB4180003) and Comissão de Ética Para Análise de Projetos de Pesquisa (CAAE 77612017.0.1001.0068.), respectively, and the local ethics committees at each investigating centre. All patients provided their written informed consent prior to participation in the studies.

### 2.2. Analysis of angiography-derived FFR

The independent core laboratory (CORRIB Core Lab, Galway, Ireland) retrospectively performed the Murray law-based QFR ( $\mu$ QFR) analysis using AngioPlus Core software (version V2, Pulse Medical, Shanghai, China).  $\mu$ QFR is a novel computational method derived from a single angiographic view that incorporates ostial side branch diameters into the computation of fractal flow division [20–25]. Methods to compute  $\mu$ QFR are described in Supplemental Method 1 [20,26]. Contrast flow velocity was automatically converted to hyperemic flow velocity, and pressure drop was calculated using fluid dynamics equations. [20]. Significant flow limitation pre-procedure was defined by a cut-off  $\mu$ QFR  $\leq 0.80$  [20], whilst an optimal physiological procedural result was defined as a post-PCI  $\mu$ QFR  $\geq 0.91$  [26].

Relative  $\mu$ QFR gain from PCI was evaluated by the percentage  $\mu$ QFR increase as follows:  $100 \times (\text{post-PCI } \mu\text{QFR} - \text{pre-PCI } \mu\text{QFR})/\text{pre-PCI } \mu\text{QFR}$  [12,27].

### 2.3. Preprocedural pathophysiological characterisation of CAD

Pre-procedural pathophysiological distribution of coronary athero-

sclerosis (“diffuseness or focality”) was assessed using  $\mu$ QFR-derived pullback pressure gradient (PPG) index calculated as follows [9,12,13] (Fig. 1, Fig. 2):

$$\mu\text{QFR} - \text{derived PPG index} = \frac{\left\{ \frac{\text{Max PPG } 20\text{mm}}{\Delta\mu\text{QFR vessel}} + \left( 1 - \frac{\text{Length with functional disease (mm)}}{\text{Total vessel length (mm)}} \right) \right\}}{2}$$

Maximal PPG was defined as the maximum  $\mu$ QFR gradient over 20 mm, and delta  $\mu$ QFR vessel as 1-vessel  $\mu$ QFR. The length with functional disease was defined as the length, in millimetres, with  $\mu$ QFR drop  $\geq 0.0015/\text{mm}$  [9]. The total vessel length was defined as the length of the entire interrogated vessel. The pre-procedural and post-procedural physiological distribution of coronary atherosclerosis was defined as predominantly diffuse or focal according to a  $\mu$ QFR-derived PPG index  $< 0.78$  or  $\geq 0.78$ , respectively [12].

The pre-PCI physiological local severity of a lesion was assessed using the  $\mu$ QFR gradient per mm ( $d\mu\text{QFR}/ds$ ) (Fig. 2), with a value  $\geq 0.025/\text{mm}$  defining the presence of a “major gradient” [12].

#### 2.4. Statistical analysis

Continuous variables are presented as mean and standard deviation (SD) or as median and interquartile range (IQR) depending on their distribution and are compared using the Student’s *t*-test or Mann-Whitney *U* test. Categorical variables are described as percentages and compared using chi-square test or Fisher exact, as appropriate.

To predict the unadjusted and adjusted risks of a post-PCI  $\mu$ QFR  $< 0.91$  in the pooled populations of the ASET Japan and ASET Brazil, we

used binary logistic regression models with age, sex, diabetes mellitus, pre-procedural  $\mu$ QFR, PPG index,  $d\mu\text{QFR}/ds$ , use of intracoronary imaging for stent optimisation, and study population (ASET Japan vs. Brazil).

To predict unadjusted and adjusted risks of a post-PCI  $\mu$ QFR  $< 0.91$  in each study population, we used binary logistic regression models with pre-procedural  $\mu$ QFR, PPG index, and  $d\mu\text{QFR}/ds$ , as continuous predictor variables.

To predict unadjusted and adjusted risks of physiological diffuse disease (pre-PCI PPG index  $< 0.78$ ), we used binary logistic regression models with age, sex, body mass index, current smoking, diabetes mellitus, hypertension, dyslipidemia, peripheral artery disease, chronic obstructive pulmonary artery disease, and renal insufficiency.

A 2-sided *p*-value  $< 0.05$  was considered statistically significant. All statistical analyses were performed using R version 4.1.3 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS version 27.0 (IBM, Armonk, NY, USA).

### 3. Results

From February 2018 to May 2019, 201 patients with 235 vessels were enrolled in the ASET Brazil study from 9 centres in Brazil. From November 2020 to September 2022, 206 patients with 217 vessels were enrolled in the ASET Japan study from 12 centres in Japan.

Baseline clinical characteristics are shown in Table 1. Patients from Japan were significantly older, and the proportion of males was significantly higher than those from Brazil. A history of dyslipidemia and renal insufficiency were more common in Japanese compared to





Fig. 1. Pre-procedural physiological distribution (“diffuseness or focality”) of coronary disease assessed using  $\mu$ QFR-derived PPG index in the ASET Japan (A) and ASET Brazil (B) studies.

In calculating the PPG index to assess the physiological distribution of coronary disease, the parameters of i)  $\frac{\text{Max PPG } 20\text{mm}}{\Delta\mu\text{QFR vessel}}$  and ii)  $\frac{\text{Length with functional disease (mm)}}{\text{Total vessel length (mm)}}$  contribute to focality and diffuseness, respectively. When the PPG index is constant, these two parameters are positively correlated with a slope of 1, which explains the various thresholds in the graphic diagram. The dashed lines show the threshold criteria of various median or mean PPG indexes: ASET Japan and ASET Brazil, median 0.68 vs. 0.67, respectively; PANDA III trial, median 0.79 [14]; Shin et al., median 0.78 [12]; TARGET-FFR and P3 study, median 0.66 [10,11]; and Collet et al., mean 0.57 [9]. PPG = pullback pressure gradient;  $\mu$ QFR = Murray law-based quantitative flow ratio.



**Case 1: Vessel with pre-procedural focal disease pattern**

**Case 2: Vessel with pre-procedural diffuse disease pattern**



**Fig. 2.** Representative cases with pre-procedural focal (Case 1) and diffuse (Case 2) disease patterns. Case 1 is a vessel which had a focal pattern of CAD pre-procedure (Pre-PCI PPG index  $\geq 0.78$ ) and a major gradient (pre-PCI  $d\mu QFR/ds \geq 0.025/mm$ ). The black curve in the graph shows the pressure gradient per mm ( $d\mu QFR/ds$ ). The cumulative pressure drop is represented by the purple curve. Case 1 resulted in an optimal  $\mu QFR$  post-PCI. Case 2 is a vessel which had a diffuse pattern of CAD pre-procedure (Pre-PCI PPG index  $< 0.78$ ) without a major gradient. Case 2 resulted in a sub-optimal post-PCI  $\mu QFR (< 0.91)$ . In this case, a residual peak  $d\mu QFR/ds$  was located distal to the stented segment with no major gradient (i.e.,  $d\mu QFR/ds < 0.025/mm$ ), and a diffuse residual pressure drop was observed along the vessel distal to the stented segment with a post-PCI PPG index  $< 0.78$ . PCI = percutaneous coronary intervention; PPG = pullback pressure gradient. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Brazilian population, whereas the opposite was observed for clinical characteristics such as hypertension and obesity. There was no significant difference in the anatomical SYNTAX score between the studies.

Lesion and procedural characteristics are shown in Supplemental Table 1. The number of patients with more than one treated lesion, as well as the number of stents and the total stent length per patient, were significantly higher in Brazillian compared to Japanese population. The use of intracoronary imaging for stent optimisation was significantly more frequent in ASET Japan than in ASET Brazil (99.6% vs. 56.0%,  $p < 0.001$ ).

In the ASET Japan study, pre-PCI  $\mu QFR$  was analysable in 207 out of 217 vessels; 10 vessels with Thrombolysis in Myocardial Infarction (TIMI)  $< 3$  flow could not be processed (Supplemental Fig. 1 A). Post-PCI  $\mu QFR$ s of all 217 vessels were analysable, resulting in 207 vessels with paired pre- and post-PCI  $\mu QFR$ .

In the ASET Brazil study, pre-PCI  $\mu QFR$  was analysable in 228 out of 235 vessels; 6 vessels with TIMI  $< 3$  flow and one without fluoroscopic acquisition of the entire target vessel could not be processed. Post-PCI

$\mu QFR$  was analysed in 231 vessels; 2 vessels with TIMI  $< 3$  flow, one without fluoroscopic acquisition of the entire target vessel, and one without available angiographic data were excluded, resulting in 227 vessels with paired pre- and post-PCI  $\mu QFR$  (Supplemental Fig. 1B).

**3.1. Comparison of the pre-procedural physiological assessment of CAD between the two studies**

The median pre-PCI  $\mu QFR$  was significantly lower in ASET Japan compared to ASET Brazil (0.71; IQR 0.58–0.78 vs. 0.77; IQR 0.64–0.83;  $p < 0.001$ , Mann-Whitney test, Table 2, Supplemental Fig. 2 A). As shown in Supplemental Fig. 2 BC, the frequency of vessels with a pre-PCI  $\mu QFR \leq 0.80$  was 89.9% (186/207) in ASET Japan and 67.5% (154/228) in ASET Brazil ( $p < 0.001$ ).

The peak  $d\mu QFR/ds$  (i.e.,  $\mu QFR$  gradient per mm) in each target vessel was higher in ASET Japan than in ASET Brazil (median 0.045/mm; IQR 0.029–0.077 vs. 0.031/mm; IQR 0.018–0.060;  $p < 0.001$ ) (Table 2).

**Table 1**  
Baseline clinical characteristics.

Baseline characteristics	Total (n = 407)	Japan (n = 206)	Brazil (n = 201)	p value
Age, years (SD)	64.3 (10.0)	69.0 (9.8)	59.5 (7.7)	<0.001
Male, % (n)	73.2 (298)	81.6 (168)	64.7 (130)	<0.001
Body mass index, kg/m <sup>2</sup> (SD)	26.7 (4.6)	24.6 (3.9)	(4.4)	<0.001
Medical history				
Current smoking, % (n)	17.0 (69) 36.4	17.5 (36)	16.4 (33)	0.776
Diabetes mellitus, % (n)	148 (148)	35.9 (74)	36.8 (74)	0.851
Insulin dependent, % (n)	7.6 (31) 86.2	7.3 (15)	8.0 (16)	0.840
Hypertension, % (n)	351 (351)	165 (165)	186 (186)	<0.001
Dyslipidemia, % (n)	77.6 (316)	85.4 (176)	69.7 (140)	<0.001
Previous MI, % (n)	11.1 (45)	13.1 (27)	9.0 (18)	0.246
PAD, % (n)	5.9 (24)	6.3 (13)	5.5 (11)	0.349
COPD, % (n)	3.4 (14)	4.9 (10)	2.0 (4)	0.094
Renal insufficiency *, % (n)	17.4 (71)	34.5 (71)	0 (0)	<0.001
Previous PCI, % (n)	18.7 (76)	24.8 (51)	12.4 (25)	0.001
Previous CABG, % (n)	1.7 (7)	1.9 (4)	1.5 (3)	0.514
LVEF, % (SD)	62.2 (9.2)	(10.0)	(7.7)	<0.001
Anatomical SYNTAX score (SD)	7.6 (4.6)	8.0 (4.6)	7.2 (4.5)	0.066

Values are mean (SD) or n (%).

\* Renal insufficiency was defined as an estimated glomerular filtration rate of creatinine clearance <60 ml/min/1.73 m<sup>2</sup>. CABG = coronary artery bypass graft; CAD = coronary artery disease; COPD = chronic obstructive pulmonary artery disease; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; SD = standard deviation; SYNTAX = Synergy Between PCI With Taxus and Cardiac Surgery.

The median PPG index was comparable between the two groups (Japan 0.68; IQR 0.60–0.79 vs. Brazil 0.67; IQR 0.59–0.77; *p* = 0.539, Mann-Whitney test)(Table 2). In calculating the PPG index to assess the physiological distribution of CAD, the parameters of i)  $\frac{Max\ PPG\ 20mm}{\Delta\mu QFR\ vessel}$  and ii)  $\frac{Length\ with\ functional\ disease\ (mm)}{Total\ vessel\ length\ (mm)}$  contribute to focality and diffuseness, respectively. The median  $\frac{Max\ PPG\ 20mm}{\Delta\mu QFR\ vessel}$  (0.76; IQR 0.60–0.87 vs. 0.71; IQR 0.59–0.82; *p* = 0.130, Mann-Whitney test) and the median  $\frac{Length\ with\ functional\ disease\ (mm)}{Total\ vessel\ length\ (mm)}$  (0.34; IQR 0.26–0.46 vs. 0.33; IQR 0.22–0.44; *p* = 0.425) were also comparable between the two groups. Therefore, as shown in Fig. 1, the distribution of the focality and diffuseness of CAD, defined by the PPG index formula, was similar between Japanese and Brazilian populations.

### 3.2. Association between pre-procedural physiological patterns and haemodynamic outcomes post-procedural in the two studies

Compared to ASET Brazil, patients in ASET Japan had a significantly higher median relative  $\mu QFR$  gain from PCI (30.7%; IQR: 21.1–54.8 vs. 24.4%; IQR 13.8–43.1; *p* < 0.001), whereas the median post-PCI  $\mu QFR$  was statistically lower in the ASET JAPAN study compared to the ASET BRAZIL study (0.94; IQR 0.91–0.96 vs. 0.95; IQR 0.92–0.97; *p* = 0.004)(Table 2). The frequency of vessels with post-PCI  $\mu QFR$  <0.91 was 22.1% (48/217) and 12.9% (30/231) in the ASET Japan and Brazil studies, respectively (*p* = 0.013)(Table 2, Supplemental Fig. 2 BC).

A pre-procedural diffuse pattern of CAD (PPG index <0.78) with a pre-PCI  $\mu QFR$  <0.80 (lower left compartment in Supplemental Fig. 3 AB) accounted for 79.2% (38/48) and 83.3% (25/30) of vessels resulting in a post-PCI  $\mu QFR$  <0.91 in ASET Japan and ASET Brazil, respectively.

In multivariable analysis of the pooled population, low pre-PCI  $\mu QFR$  (per 0.1 decrease; odds ratio [OR] 1.53, 95% confidence interval [CI]

**Table 2**  
Physiological characteristics.

	Japan	Brazil	p value
Pre-PCI $\mu QFR$ (IQR)	(n = 207) 0.71 (0.58–0.78)	(n = 228) 0.77 (0.64–0.83)	<0.001
$\mu QFR \leq 0.80$ , % (n)	89.9 (186)	67.5 (154)	<0.001
Peak $d\mu QFR/ds$ , /mm (IQR)	0.045 (0.029–0.077)	0.031 (0.018–0.060)	<0.001
PPG index	0.68 (0.60–0.79)	0.67 (0.59–0.77)	0.539
PPG index <0.78, % (n)	72.5 (150)	76.8 (175)	0.322
Max PPG 20 mm/ $\Delta\mu QFR$ vessel (IQR)	0.76 (0.60–0.87)	0.71 (0.59–0.82)	0.130
Length with functional disease/ Total vessel length (IQR)	0.34 (0.26–0.46)	0.33 (0.22–0.44)	0.425
Post-PCI $\mu QFR$ (IQR)	(n = 217) 0.94 (0.91–0.96)	(n = 231) 0.95 (0.92–0.97)	0.004
$\mu QFR < 0.91$ , % (n)	22.1 (48)	12.9 (30)	0.013
Relative $\mu QFR$ gain, % (IQR) *	30.7 (21.1–54.8)	24.4 (13.8–43.1)	<0.001
Post-PCI <0.91	(n = 48)	(n = 30)	
Pre-procedural diffuse pattern, % (n) #	83.3 (40)	86.7 (26)	
Residual diffuse pressure drop post-procedure, % (n) †	85.4 (41)	90.0 (27)	
Residual major gradient, % (n)	2.1 (1)	6.7 (2)	
Site of residual peak $d\mu QFR/ds$ , % (n)			
Proximal to the stented segment	39.6 (19)	40.0 (12)	
Stented segment	2.1 (1)	6.7 (2)	
Distal to the stented segment	58.3 (28)	53.3 (16)	

Values are median (IQR) or % (n).

\* A relative  $\mu QFR$  gain was calculated in 207 and 227 vessels with paired pre- and post-PCI  $\mu QFR$  in the ASET Japan and the ASET Brazil study, respectively.

# Pre-procedural diffuse pattern was defined as pre-PCI PPG index <0.78.

† Residual diffuse pressure drop was defined as post-PCI PPG index <0.78.  $d\mu QFR/ds$  =  $\mu QFR$  gradient per mm; IQR = interquartile range; PCI = percutaneous coronary intervention; PPG = pullback pressure gradient;  $\mu QFR$  = Murray law-based quantitative flow ratio.

1.13–2.10, *p* = 0.008) and low pre-PCI PPG index (per 0.1 decrease; OR 1.85, 95% CI 1.39–2.50, *p* < 0.001) were independent risk factors for predicting a post-PCI  $\mu QFR$  <0.91, whereas the use of intracoronary imaging for stent optimisation was not (OR 1.12, 95% CI 0.35–3.17, *p* = 0.833)(Supplemental Table 2). Although there were significant differences in achieving post-PCI  $\mu QFR \geq 0.91$  between the two studies in univariate analyses, it was no longer significant after adjustment by pre-PCI  $\mu QFR$  and pre-PCI PPG index (OR 1.46, 95% CI 0.52–4.68, *p* = 0.497). In both studies, the pre-PCI PPG index was an independent risk factor for predicting a post-PCI  $\mu QFR$  <0.91 (per 0.1 decrease of PPG index, ASET Japan: OR 1.64, 95% CI 1.14–2.42, *p* = 0.008; ASET Brazil: OR 2.27, 95% CI 1.43–3.71, *p* < 0.001)(Table 3, Fig. 2).

### 3.3. Distribution of residual pressure drop in the ASET Japan and ASET Brazil studies

Among vessels with post-PCI  $\mu QFR$  <0.91, a consistent diffuse pattern of CAD pre- and post-PCI was seen in 78.3% (36/46) and 76.7% (23/30) of vessels in ASET Japan and Brazil, respectively (lower left compartment in Fig. 3 AB); only 6.3% (3/48) and 10.0% (3/30) of vessels in the respective studies had a residual major gradient ( $\mu QFR/ds \geq 0.025/mm$ ).


Among vessels with post-PCI  $\mu QFR$  <0.91, residual peak  $d\mu QFR/ds$  was located proximal to the stented segment in 39.6% (19/48) and 40.0% (12/30), distal to the segment in 58.3% (28/48) and 53.3% (16/30), and in stented segment in only 2.1% (1/48) and 6.7% (2/30) of vessels in ASET Japan and Brazil, respectively (Fig. 3 CD, Table 2).

**Table 3**

Association between pre-procedural physiological characteristics and post-PCI  $\mu$ QFR <0.91 in the ASET Japan and ASET Brazil studies.

	Risk for post-PCI $\mu$ QFR <0.91							
	ASET Japan				ASET Brazil			
	Univariable analysis		Multivariable analysis		Univariable analysis		Multivariable analysis	
	OR (95% CI)	p value	OR (95% CI)	p value	OR (95% CI)	p value	OR (95% CI)	p value
Pre-PCI $\mu$ QFR, per 0.1 decrease	1.31 (1.07–1.61)	0.006†	1.46 (0.97–2.22)	0.070	1.53 (1.23–1.92)	<0.001†	1.51 (0.95–2.51)	0.092
Pre-PCI PPG index, per 0.1 decrease	1.50 (1.16–1.97)	0.001†	1.64 (1.14–2.42)	0.008†	2.14 (1.53–3.11)	<0.001†	2.27 (1.43–3.71)	<0.001†
Pre-PCI $d\mu$ QFR/ds, per 0.01/mm increase	1.02 (0.95–1.09)	0.531	0.99 (0.83–1.17)	0.957	1.06 (0.96–1.16)	0.189	1.05 (0.82–1.31)	0.663

Adjusted covariates included pre-procedural  $\mu$ QFR,  $\mu$ QFR-PPG index, and  $d\mu$ QFR/ds. CI = confidence interval;  $d\mu$ QFR/ds =  $\mu$ QFR gradient per mm; OR = odds ratio; PCI = percutaneous coronary intervention; PPG = pullback pressure gradient;  $\mu$ QFR = Murray law-based quantitative flow ratio.



**Fig. 3.** The distribution of pre- and post-PCI PPG index (A, B) and sites of the residual peak  $d\mu$ QFR/ds (C, D) among vessels with post-PCI  $\mu$ QFR <0.91 in the ASET Japan and ASET Brazil studies.

Among vessels with a post-PCI  $\mu$ QFR <0.91, a consistent diffuse pattern of CAD pre- and post-PCI was seen in 78.3% (36/46) and 76.7% (23/30) of vessels (lower left compartment) in ASET Japan (A) and ASET Brazil (B), respectively. Case 2 with a diffuse pattern is shown in Fig. 2. Among vessels with post-PCI  $\mu$ QFR <0.91, residual peak  $d\mu$ QFR/ds was located in only 2.1% (1/48) and 6.7% (2/30) of vessels in ASET Japan (C) and Brazil (D), respectively.  $d\mu$ QFR/ds =  $\mu$ QFR gradient per mm; PCI = percutaneous coronary intervention; PPG = pullback pressure gradient.

**3.4. Association between clinical baseline characteristics and physiological diffuse disease in the ASET Japan and ASET Brazil studies**

The association between clinical baseline characteristics and a pre-procedural physiological diffuse pattern of CAD in the ASET Japan

and ASET Brazil studies are shown in Table 4. In the multivariable analysis, diabetes mellitus was an independent risk factor for diffuse disease in ASET Japan (OR 3.10, 95% CI 1.45–7.13,  $p = 0.005$ ), whereas age (per 1-year increase: OR 1.09, 95% CI 1.04–1.14,  $p < 0.001$ ) and sex (male: OR 2.68, 95% CI 1.25–6.17,  $p = 0.015$ ) were independent risk



**Table 4**

Association between clinical baseline characteristics and physiological diffuse disease in the ASET Japan and ASET Brazil studies.

	Risk for physiological diffuse disease (pre-PCI PPG index <0.78)							
	ASET Japan				ASET Brazil			
	Univariable analysis		Multivariable analysis		Univariable analysis		Multivariable analysis	
	OR (95% CI)	p value	OR (95% CI)	p value	OR (95% CI)	p value	OR (95% CI)	p value
Age, per 1y increase	1.02 (0.99–1.06)	0.132	1.01 (0.98–1.05)	0.497	1.09 (1.04–1.14)	<0.001†	1.09 (1.04–1.14)	<0.001†
Male	1.22 (0.56–2.92)	0.630	1.14 (0.48–2.90)	0.779	2.50 (1.26–5.28)	0.011†	2.68 (1.25–6.17)	0.015†
BMI, per 1 kg/m <sup>2</sup> increase	1.01 (0.94–1.10)	0.735	1.00 (0.92–1.10)	0.950	0.99 (0.93–1.07)	0.840	1.00 (0.93–1.09)	0.968
Current smoking	0.79 (0.37–1.74)	0.538	0.80 (0.35–1.88)	0.606	0.72 (0.33–1.67)	0.419	0.96 (0.40–2.45)	0.932
Diabetes mellitus	3.69 (1.80–8.24)	<0.001†	3.10 (1.45–7.13)	0.005†	1.51 (0.79–2.97)	0.225	1.14 (0.53–2.49)	0.739
Hypertension	1.70 (0.81–3.49)	0.150	1.30 (0.58–2.84)	0.513	2.11 (0.69–5.98)	0.169	2.13 (0.62–6.92)	0.210
Dyslipidemia	1.84 (0.81–4.05)	0.135	1.38 (0.58–3.19)	0.450	0.74 (0.36–1.45)	0.397	0.63 (0.29–1.32)	0.233
PAD	1.20 (0.46–4.04)	0.731	1.28 (0.43–4.64)	0.677	2.05 (0.54–13.4)	0.356	1.34 (0.31–9.37)	0.727
COPD	0.65 (0.19–2.56)	0.503	0.69 (0.18–2.89)	0.586	0.60 (0.11–4.39)	0.557	0.18 (0.03–1.50)	0.078
Renal insufficiency *	3.28 (0.89–21.2)	0.121	1.95 (0.48–13.2)	0.406	–	–	–	–

Adjusted covariates included age, sex, BMI, current smoking, diabetes mellitus, hypertension, dyslipidemia, PAD, COPD, and renal insufficiency. Since no patients had renal insufficiency, it was not included in the adjusted covariates for the analysis of the ASET Brazil. \* Renal insufficiency was defined as an estimated glomerular filtration rate of creatinine clearance <60 ml/min/1.73 m<sup>2</sup>. BMI = body mass index; CI = confidence interval; OR = odds ratio; COPD = chronic obstructive pulmonary artery disease; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; PPG = pullback pressure gradient.

factors in ASET Brazil.

#### 4. Discussion

##### 4.1. Comparison of pre-procedural pathophysiological characteristics and their association with haemodynamic outcomes post-procedure between the two studies

Pre-PCI  $\mu$ QFR was significantly lower in ASET Japan than in ASET Brazil (0.71; IQR 0.58–0.78 vs. 0.77; IQR 0.64–0.83;  $p < 0.001$ ). The physiological distribution of coronary atherosclerosis characterising “focality and diffuseness” was similar between the two studies (median PPG index 0.68 vs. 0.67 in ASET Japan and ASET Brazil, respectively).

Collet et al. reported that the mean PPG index derived from *invasive* pressure pullbacks during continuous hyperemia was 0.57 (SD: 0.18) [9]. Shin et al. reported that the median PPG index derived from *angiography*-based FFR was 0.78 (IQR: 0.71–0.85) in a multicenter study in the Far East [12](Fig. 1). They also observed that predominantly diffuse disease (QFR-derived PPG index <0.78) was an independent predictor of sub-optimal physiological results post-PCI, and that the rate of target vessel failure after PCI was significantly higher in patients with predominantly diffuse, as opposed to predominant focal disease. Indeed, in both the ASET Japan and Brazil studies, more than 80% of vessels with a suboptimal post-PCI  $\mu$ QFR had a physiological diffuse pattern of CAD pre-PCI. Our findings show that, as a continuous metric, a low  $\mu$ QFR-derived PPG index was an independent factor for predicting suboptimal haemodynamic outcomes immediately after PCI, which was consistent in both studies.

##### 4.2. Combined pre-procedural physiological assessment of vessel $\mu$ QFR and diffuseness of CAD

When the population was further stratified by pre-PCI  $\mu$ QFR ( $\leq 0.80$  vs.  $> 0.80$ ) and pre-PCI PPG index ( $< 0.78$  vs.  $\geq 0.78$ ), the proportion of the vessels with predominantly diffuse disease (PPG index <0.78) without a significant pre-PCI  $\mu$ QFR ( $> 0.80$ ) — which can be interpreted as vessels having a diffuse disease with  $\mu$ QFR drop  $\geq 0.0015$ /mm, but without a significant cumulative pressure drop along the whole target vessel — was more frequent in ASET Brazil (25.9%) than ASET Japan (7.2%) (Supplemental Fig. 3AB). It is unknown whether revascularisation could be safely deferred in these vessels; nevertheless, they would benefit from aggressive preventative therapy. In both studies, enrolment was based on investigators' discretion, although inclusion criteria required evidence of myocardial ischemia (positive non-invasive testing showing ischemia) and/or symptoms. Whilst a  $\mu$ QFR  $> 0.80$  in a target

vessel would suggest the absence of ischaemia, and therefore PCI might be questionable, it remains plausible that diffuse CAD might actually cause symptoms. Even in the ASET Japan study, the presence of myocardial ischemia was assessed by wire-FFR, non-hyperemic pressure ratio (NHPR), or FFR<sub>CT</sub> in only 25.2% (52), 18.4% (38), and 19.4% (40) of patients, respectively. Considering the feasibility of pre-PCI  $\mu$ QFR computation in the present study, angiography-based FFR may serve as a tool to facilitate the implementation of physiological assessment in clinical practice. In addition, Warisawa et al. reported that the physiological predominantly diffuse CAD pattern was significantly associated with discordance between FFR and instantaneous wave-free ratio (iFR) [28]. This finding suggested that in physiological diffuse disease, frictional losses along the length of the vessel would be the primary mode of pressure energy loss, evident at rest (iFR+) with only a minimal increase during hyperemia (FFR-) [28]. While the present study identified an association between a diffuse pattern and immediate hemodynamic outcomes post-PCI, further clinical studies incorporating both pre-procedural pathophysiological CAD patterns and pre-PCI FFR/iFR/angiography-based FFR are warranted to evaluate its impact on long-term clinical outcomes and to determine the best strategies.

Conversely, ASET Japan included more vessels with predominantly focal disease (PPG index  $\geq 0.78$ ) and a significant pre-PCI  $\mu$ QFR ( $\leq 0.80$ ) than ASET Brazil (Supplemental Fig. 3AB). These vessels could be expected to benefit from stenting. In addition, it has been reported that the steep gradient of pressure drop, which is considered a physiological local severity of coronary atherosclerosis, could be a predictor of FFR gain reflecting the degree of physiological benefit from PCI [12,29]. The physiological local severity of CAD defined by peak  $d\mu$ QFR/ds was higher in ASET Japan than ASET Brazil (0.045/mm, IQR 0.029–0.077 vs. 0.031/mm, IQR 0.018–0.060;  $p < 0.001$ ), resulting in the significantly higher relative  $\mu$ QFR gain from PCI (ASET Japan: 30.7%, IQR 21.1–54.8 vs. ASET Brazil: 24.4%, IQR 13.8–43.1,  $p < 0.001$ ). On the contrary, there was no significant difference between the two populations in pre-procedural percent diameter stenosis by QCA analysis, which is a conventional, but rather non-specific parameter of the anatomical local severity of coronary atherosclerosis.

##### 4.3. Comparison of the site of residual pressure drop post-procedure between two studies

In vessels with post-PCI  $\mu$ QFR  $< 0.91$ , over 90% of vessels in both two studies had the residual peak  $d\mu$ QFR/ds in non-stented segments, with distal to the stented segment most common. Conventional strategies to optimise the overall haemodynamic outcome include post-dilatation of the stent, or if this proves ineffective, additional stenting or use of a drug



coated balloon in non-stented segments. However, over 85% of vessels in the two studies with a suboptimal post-PCI  $\mu$ QFR ( $<0.91$ ) had a residual diffuse pressure drop post-PCI according to the PPG index ( $<0.78$ ), and less than 10% had a residual major gradient ( $\mu$ QFR/ds  $\geq 0.025/\text{mm}$ ). Hence these vessels are unlikely to benefit from additional stenting due to the widespread and steady residual pressure drop without any steep identifiable gradient.

#### 4.4. Predictive risk for sub-optimal haemodynamic outcomes immediately post-procedure

The median post-PCI  $\mu$ QFR was statistically lower in ASET Japan than in ASET Brazil. However, in the multivariable analysis of the pooled population of both studies, when pre-PCI  $\mu$ QFR and pre-PCI PPG index were included as adjusted covariates, the study population had no impact on the risk of sub-optimal haemodynamic outcomes. This suggests that the lower pre-PCI  $\mu$ QFR in the ASET Japan population impacted the difference in post-PCI  $\mu$ QFR between the two populations. The use of intracoronary imaging for stent optimisation was not directly associated with a reduction in the risk of suboptimal haemodynamic outcomes. A possible explanation for this is that residual lesions were disseminated along the entire vessel, and not localised to a focal point that could be easily detected by intracoronary imaging and receive additional percutaneous treatment. Of note, both populations had a relatively high prevalence of a diffuse pattern of CAD, with lower median values of pre-procedural angiography-derived PPG index when compared to previous reports [12,14].

#### 4.5. Predictive risk factors of physiological diffuse disease and its geographic disparity

There was a geographic disparity in the clinical risk factors associated with physiological diffuse disease in the two study populations. In the ASET Japan population, the independent risk factor was diabetes mellitus, which is modifiable, while in ASET Brazil it was age and sex. Given that the physiological diffuse pattern of CAD was associated with sub-optimal results post-PCI, attention should be focused on controlling these modifiable risk factors of the development and progression of diffuse disease. Furthermore, predictive biomarkers for diffuse disease warrant investigation in future studies to detect optimal targets for prevention using powerful antiatherogenic therapy such as micro-RNA inhibiting PCSK-9, lipoprotein (a), high-sensitivity C-reactive protein, and IL-6 [30], whilst considering geographic disparities.

#### 4.6. Study limitations

Angiography-derived FFR was analysed retrospectively, and the results of this proof-of-concept study are only hypothesis-generating. This is a specific population of CCS, and the findings are not applicable to acute coronary syndrome or other indications. Invasive FFR as the gold standard of physiological assessment for intermediate coronary stenosis was not performed, although excellent correlation of  $r = 0.90$  ( $p < 0.001$ ) and agreement (mean difference: 0.00 [SD: 0.05],  $p = 0.378$ ; intraclass correlation coefficient for the absolute value = 0.91 [95% CI: 0.89–0.92]) with wire-based FFR have been shown [20].

## 5. Conclusions

There was a geographic disparity in preprocedural angiography-based pathophysiological characteristics. The combined preprocedural physiological assessment of vessel  $\mu$ QFR and diffuseness/focality of CAD potentially identifies patients who will benefit most from PCI.

## Funding support and author disclosures

The ASET Japan study was sponsored by Meditrix with grants from Boston Scientific Japan. The ASET Pilot (ASET Brazil) study was sponsored by InCor with grants from Boston Scientific and Daiichi-Sankyo. The grant givers had no role in the study design, data collection, analyses, and interpretation of the study data and were not involved in the decision to publish the final manuscript. Dr Kotoku has received a grant for studying overseas from Fukuda Foundation for Medical Technology. Dr Ninomiya has received a grant from Abbott Medical Japan outside the submitted work. Dr Masuda has received a grant from Terumo outside the submitted work. Dr Tu is a co-founder of Pulse Medical and received institutional research grants from Pulse Medical. Dr Kozuma has received an honorarium for lectures and advisory boards from Daiichi-Sankyo and Boston Scientific. Dr Nakamura has received lecture fees from Boston Scientific Japan, Terumo, Daiichi Sankyo, and Bayer, and has affiliations with Endowed Department from Boston Scientific Japan, Kaneka, Terumo, Nipro, Ostuka Medical Device, Japan Lifeline, Asahi Intec, and Biotronic Japan. Dr Morino has received an honorarium for lectures and an unrestricted research grant from Boston Scientific. Dr Ishida has received an honorarium for lectures from Boston Scientific Japan. Dr Tanabe has received an honorarium for lectures from Daiichi Sankyo and Boston Scientific. Dr Garg has received consultancy fees from Biosensors. Dr Muramatsu has received an honorarium from Boston Scientific Japan and Daiichi Sankyo. Dr Serruys is a consultant for Philips/Volcano, SMT, Novartis, Xeltis, and Meril Life. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

## CRedit authorship contribution statement

**Nozomi Kotoku:** Conceptualization, Data curation, Formal analysis, Methodology, Visualization, Writing – original draft. **Kai Ninomiya:** Conceptualization, Formal analysis, Methodology, Writing – original draft. **Shinichiro Masuda:** Data curation, Formal analysis, Project administration, Writing – review & editing. **Tsung Ying Tsai:** Formal analysis, Writing – review & editing. **Pruthvi C. Revaiah:** Formal analysis, Writing – review & editing. **Scot Garg:** Writing – original draft. **Shigetaka Kageyama:** Formal analysis, Writing – review & editing. **Shengxian Tu:** Software, Writing – review & editing. **Ken Kozuma:** Investigation, Writing – review & editing. **Hideyuki Kawashima:** Investigation, Writing – review & editing. **Yuki Ishibashi:** Investigation, Writing – review & editing. **Gaku Nakazawa:** Investigation, Writing – review & editing. **Kuniaki Takahashi:** Investigation, Writing – review & editing. **Takayuki Okamura:** Investigation, Writing – review & editing. **Yosuke Miyazaki:** Investigation, Writing – review & editing. **Hiroki Tateishi:** Investigation, Writing – review & editing. **Masato Nakamura:** Investigation, Writing – review & editing. **Norihiro Kogame:** Investigation, Writing – review & editing. **Taku Asano:** Investigation, Writing – review & editing. **Shimpei Nakatani:** Investigation, Writing – review & editing. **Yoshihiro Morino:** Investigation, Writing – review & editing. **Masaru Ishida:** Investigation, Writing – review & editing. **Yuki Katagiri:** Investigation, Writing – review & editing. **Fernando De Martino:** Investigation, Writing – review & editing. **João Tinoco:** Investigation, Writing – review & editing. **Patricia O. Guimarães:** Investigation, Writing – review & editing. **Kengo Tanabe:** Investigation, Writing – review & editing. **Yukio Ozaki:** Investigation, Writing – review & editing. **Takashi Muramatsu:** Investigation, Writing – review & editing. **Pedro A. Lemos:** Investigation, Project administration, Writing – review & editing. **Yoshinobu Onuma:** Conceptualization, Methodology, Project administration, Supervision, Writing – original draft. **Patrick W. Serruys:** Conceptualization, Methodology, Writing – original draft, Project administration, Supervision.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijcard.2024.131805>.

## References

- [1] M. Vaduganathan, G.A. Mensah, J.V. Turco, V. Fuster, G.A. Roth, The global burden of cardiovascular diseases and risk: a compass for future health, *J. Am. Coll. Cardiol.* 80 (2022) 2361–2371.
- [2] R.O. Bonow, D.L. Mann, D.P. Zipes, P. Libby, *Braunwald's Heart Disease e-Book: A Textbook of Cardiovascular Medicine*, Elsevier Health Sciences, 2011.
- [3] Y. Onuma, T. Kimura, L. Räber, et al., Differences in coronary risk factors, procedural characteristics, mortality and stent thrombosis between two all-comers percutaneous coronary intervention registries from Europe and Japan: a patient-level data analysis of the Bern-Rotterdam and j-cypher registries, *EuroIntervention* 11 (2015) 533–540.
- [4] G.W. Stone, A. Abizaid, Y. Onuma, et al., Effect of technique on outcomes following Bioresorbable vascular scaffold implantation: analysis from the ABSORB trials, *J. Am. Coll. Cardiol.* 70 (2017) 2863–2874.
- [5] S. Kohsaka, T. Kimura, M. Goto, et al., Difference in patient profiles and outcomes in Japanese versus American patients undergoing coronary revascularization (collaborative study by CREDO-Kyoto and the Texas heart institute research database), *Am. J. Cardiol.* 105 (2010) 1698–1704.
- [6] S. Echeverria, M.T. Alam, Why heterogeneity matters: prevention implications of excess diabetes-related deaths in Asian American subgroups, *JACC Asia* 3 (2023) 373–375.
- [7] N. Kogame, M. Ono, H. Kawashima, et al., The impact of coronary physiology on contemporary clinical decision making, *J. Am. Coll. Cardiol. Intv.* 13 (2020) 1617–1638.
- [8] S. Biscaglia, F.M. Verardi, M. Tebaldi, et al., QFR-based virtual PCI or conventional angiography to guide PCI: the AQVA trial, *JACC Cardiovasc. Interv.* 16 (2023) 783–794.
- [9] C. Collet, J. Sonck, B. Vandelooy, et al., Measurement of hyperemic pullback pressure gradients to characterize patterns of coronary atherosclerosis, *J. Am. Coll. Cardiol.* 74 (2019) 1772–1784.
- [10] C. Collet, D. Collison, T. Mizukami, et al., Differential improvement in angina and health-related quality of life after PCI in focal and diffuse coronary artery disease, *JACC Cardiovasc. Interv.* 15 (2022) 2506–2518.
- [11] T. Mizukami, J. Sonck, K. Sakai, et al., Procedural outcomes after percutaneous coronary interventions in focal and diffuse coronary artery disease, *J. Am. Heart Assoc.* 11 (2022) e026960.
- [12] D. Shin, N. Dai, S.H. Lee, et al., Physiological distribution and local severity of coronary artery disease and outcomes after percutaneous coronary intervention, *JACC Cardiovasc. Interv.* 14 (2021) 1771–1785.
- [13] N. Dai, R. Zhang, N. Hu, et al., Integrated coronary disease burden and patterns to discriminate vessels benefiting from percutaneous coronary intervention, *Catheter. Cardiovasc. Interv.* 99 (2022) E12–e21.
- [14] N. Dai, S. Yuan, K. Dou, et al., Prognostic implications of PreStent pullback pressure gradient and Poststent quantitative flow ratio in patients undergoing percutaneous coronary intervention, *J. Am. Heart Assoc.* 11 (2022) e024903.
- [15] N. Kotoku, K. Ninomiya, S. Masuda, et al., Preprocedural physiological assessment of coronary disease patterns to predict haemodynamic outcomes post-PCI, *EuroIntervention* 19 (2023) e891–e902.
- [16] S. Masuda, T. Muramatsu, Y. Ishibashi, et al., Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in east Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study, *AsiaIntervention* 9 (2023) 39–48.
- [17] T. Muramatsu, S. Masuda, N. Kotoku, et al., Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium Everolimus eluting stent for Japanese patients with chronic coronary syndrome (ASET-JAPAN), *Circ.* J. 87 (2023) 857–865.
- [18] N. Kogame, R. Modolo, M. Tomaniak, et al., Prasugrel monotherapy after PCI with the SYNERGY stent in patients with chronic stable angina or stabilised acute coronary syndromes: rationale and design of the ASET pilot study, *EuroIntervention* 15 (2019) e547–e550.
- [19] N. Kogame, P.O. Guimarães, R. Modolo, et al., Aspirin-free Prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study, *JACC Cardiovasc. Interv.* 13 (2020) 2251–2262.
- [20] S. Tu, D. Ding, Y. Chang, C. Li, W. Wijns, B. Xu, Diagnostic accuracy of quantitative flow ratio for assessment of coronary stenosis significance from a single angiographic view: a novel method based on bifurcation fractal law, *Catheter. Cardiovasc. Interv.* 97 (2021) 1040–1047.
- [21] D. Ding, S. Tu, Y. Chang, C. Li, B. Xu, W. Wijns, Quantitative flow ratio based on Murray fractal law: accuracy of single versus two angiographic views, *J. Soci. Cardiovasc. Angiograph. & Intervent.* 1 (2022) 100399.
- [22] R. Zhang, B. Xu, K. Dou, et al., Post-PCI outcomes predicted by pre-intervention simulation of residual quantitative flow ratio using augmented reality, *Int. J. Cardiol.* 352 (2022) 33–39.
- [23] S. Tu, B. Xu, L. Chen, et al., Short-term risk stratification of non-flow-limiting coronary stenosis by Angiographically derived Radial Wall strain, *J. Am. Coll. Cardiol.* 81 (2023) 756–767.
- [24] H.Y. Wang, R. Zhang, K. Dou, et al., Left main bifurcation stenting: impact of residual ischaemia on cardiovascular mortality, *Eur. Heart J.* 44 (2023) 4324–4336.
- [25] N. Kotoku, K. Ninomiya, D. Ding, et al., Murray law-based quantitative flow ratio to assess left main bifurcation stenosis: selecting the angiographic projection matters, *Int. J. Card. Imaging.* 40 (2024) 195–206.
- [26] N. Kogame, K. Takahashi, M. Tomaniak, et al., Clinical implication of quantitative flow ratio after percutaneous coronary intervention for 3-vessel disease, *JACC Cardiovasc. Interv.* 12 (2019) 2064–2075.
- [27] A. Jeremias, J.E. Davies, A. Maehara, et al., Blinded physiological assessment of residual ischemia after successful angiographic percutaneous coronary intervention: the DEFINE PCI study, *JACC Cardiovasc. Interv.* 12 (2019) 1991–2001.
- [28] T. Warisawa, C.M. Cook, J.P. Howard, et al., Physiological pattern of disease assessed by pressure-wire pullback has an influence on fractional flow reserve/instantaneous wave-free ratio discordance, *Circ. Cardiovasc. Interv.* 12 (2019) e007494.
- [29] S.H. Lee, D. Shin, J.M. Lee, et al., Automated algorithm using pre-intervention fractional flow reserve pullback curve to predict post-intervention physiological results, *JACC Cardiovasc. Interv.* 13 (2020) 2670–2684.
- [30] P.W. Serruys, S. Kageyama, S. Garg, Y. Onuma, In the beginning there was angina pectoris, at the end there was still angina pectoris, *JACC Cardiovasc. Interv.* 15 (2022) 2519–2522.